Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elan Prialt pricing

Executive Summary

Annualized price for Elan's non-opioid pain agent Prialt (ziconotide) for typical patient weighing 70 kg is $18,250, assuming dosing every six weeks. Elan describes Prialt rollout as a "quiet launch" focusing on 50 pain centers. FDA approved the product Dec. 28 and Elan launched the week of Jan. 24 (1"The Pink Sheet" Jan. 3, 2005, p. 4)...

You may also be interested in...

Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump

Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations

US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

Warning Letter Close-Outs – February 2021

No device-related close-out letters were released by the US FDA last month.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts